Mission Bio

Investment area

Growth Investments


North America

Date of investment

July 2020

Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

Visit site


Robert Ghenchev

Managing Partner

Departments: Growth Investments, Novo Holdings Equity US Inc., Life Sciences Operating Committee

Robert joined Novo Holdings in January 2018 and serves as a Managing partner and head of  Growth Investments.

Before joining Novo Holdings, Robert was a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the Healthcare Industry. Prior to Moelis, Robert was part of the UK Mergers & Acquisitions team at Deutsche Bank in London.

Robert holds a J.Hons. B.A. degree in Finance and Economics from McGill University and a M.Sc. degree in Financial Economics from the University of Oxford.